Trends in using mesenchymal stromal/stem cells (MSCs) in treating corneal diseases
Authors:
- 12 October 2022
- journal article
- research article
- Published by Elsevier in The Ocular Surface
- Vol. 26, 255-267
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Eye Institute (EY029427)
- Ohio Lions Eye Research Foundation
This publication has 101 references indexed in Scilit:
- Inter-α-inhibitor Impairs TSG-6-induced Hyaluronan Cross-linkingJournal of Biological Chemistry, 2013
- Differentiation Potential of Limbal Fibroblasts and Bone Marrow Mesenchymal Stem Cells to Corneal Epithelial CellsStem Cells, 2013
- Origins and Properties of Dental, Thymic, and Bone Marrow Mesenchymal Cells and Their Stem CellsPLOS ONE, 2012
- Dual origin of mesenchymal stem cells contributing to organ growth and repairProceedings of the National Academy of Sciences, 2011
- Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injuryProceedings of the National Academy of Sciences, 2010
- Autoimmunity at the ocular surface: pathogenesis and regulationMucosal Immunology, 2010
- Stem Cell Therapy Restores Transparency to Defective Murine CorneasStem Cells, 2009
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Cytokines, Inflammation, and PainInternational Anesthesiology Clinics, 2007
- Differential Roles of CD8* and CD8* T Lymphocytes in Corneal Allograft Rejection in ‘High-Risk’ HostsAmerican Journal of Transplantation, 2006